Hookipa Pharma Share Price Today
(NASDAQ: HOOK)

Name: Hookipa Pharma Share Price Today (NASDAQ: HOOK) - Hookipa Pharma Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Hookipa Pharma share price is $1.88 & ₹163.74 as on 5 Feb 2025, 2.30 'hrs' IST

$1.88

▲

-0.03

(-1.57%)

Market is closed - opens 8 PM, 05 Feb 2025

View live Hookipa Pharma share price in Dollar and Rupees. Guide to invest in Hookipa Pharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Hookipa Pharma, along with analyst recommendations, forecasts, and comprehensive financials.

Hookipa Pharma share price movements

Today's Low: $1.84
Today's High: $1.94
$1.88
2.39%
Downside
Day's Volatility :5.41%
Upside
3.09%
52 Weeks Low: $1.72
52 Weeks High: $10.50
$1.88
8.78%
Downside
52 Weeks Volatility :83.67%
Upside
82.1%

Hookipa Pharma (HOOK) Returns

Period	Hookipa Pharma Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-50.26%	0.5%	0.0%
6 Months	-61.1%	-2.3%	0.0%
1 Year	-71.49%	3.8%	0.0%
3 Years	-85.53%	11.4%	-11.7%

Hookipa Pharma (HOOK) Key Statistics

in dollars & INR

Previous Close	$1.91
Open	$1.9
Today's High	$1.94
Today's Low	$1.835
Market Capitalization	$23.6M
Today's Volume	$51.9K
52 Week High	$10.5
52 Week Low	$1.715
Revenue TTM	$52.2M
EBITDA	$-47.7M
Earnings Per Share (EPS)	$-3.67
Profit Margin	-93.16%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-48.99%

How to invest in Hookipa Pharma Stock (HOOK) from India?

It is very easy for Indian residents to invest directly in Hookipa Pharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Hookipa Pharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Hookipa Pharma or HOOK on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Hookipa Pharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Hookipa Pharma shares which would translate to 0.463 fractional shares of Hookipa Pharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Hookipa Pharma, in just a few clicks!

Returns in Hookipa Pharma (HOOK) for Indian investors in Rupees

The Hookipa Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Hookipa Pharma investment value today

Current value as on today

₹32,924

Returns

₹67,076

(-67.08%)

Returns from Hookipa Pharma Stock

₹71,940 (-71.94%)

Dollar Returns

₹4,865 (+4.86%)

Indian investors sentiment towards Hookipa Pharma (HOOK)

40%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Hookipa Pharma Stock from India on INDmoney has increased by 40% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Hookipa Pharma

Baker Bros Advisors LP
6.74%
EcoR1 Capital, LLC
4.74%
Siren, L.L.C.
4.70%
FMR Inc
2.83%
Vanguard Group Inc
1.77%
Redmile Group, LLC
0.88%

Analyst Recommendation on Hookipa Pharma

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Hookipa Pharma(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Hookipa Pharma Stock (HOOK)

What analysts predicted

Upside of 139.36%

Target:

$4.50

Current:

$1.88

Insights on Hookipa Pharma Stock (Ticker Symbol: HOOK)

Price Movement
In the last 3 months, HOOK stock has moved down by -49.2%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.29M → 4.70M (in $), with an average increase of 72.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -19.09M → -13.84M (in $), with an average increase of 38.0% per quarter
HOOK vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.6% return, outperforming this stock by 130.5%
HOOK vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 88.8% return, outperforming this stock by 173.6%
Price to Sales
ForHOOK every $1 of sales, investors are willing to pay $0.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.6 for every $1 of sales.

HOOK Hookipa Pharma Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$7.6M	-
Net Income	$-16.2M	↑ 27.62%
Net Profit Margin	-212.83%	-

	FY19	Y/Y Change
Revenue	$11.9M	↑ 56.53%
Net Income	$-34.1M	↑ 110.3%
Net Profit Margin	-285.94%	↓ 73.11%

	FY20	Y/Y Change
Revenue	$19.6M	↑ 63.99%
Net Income	$-33.8M	↓ 1.01%
Net Profit Margin	-172.59%	↑ 113.35%

	FY21	Y/Y Change
Revenue	$18.4M	↓ 5.8%
Net Income	$-75.7M	↑ 123.86%
Net Profit Margin	-410.16%	↓ 237.57%

	FY22	Y/Y Change
Revenue	$14.2M	↓ 22.76%
Net Income	$-65.1M	↓ 13.9%
Net Profit Margin	-457.19%	↓ 47.03%

	FY23	Y/Y Change
Revenue	$20.1M	↑ 41.27%
Net Income	$-81.6M	↑ 25.23%
Net Profit Margin	-405.29%	↑ 51.9%

	Q2 FY23	Q/Q Change
Revenue	$2.7M	↓ 15.65%
Net Income	$-18.0M	↓ 9.4%
Net Profit Margin	-672.49%	↓ 46.39%

	Q3 FY23	Q/Q Change
Revenue	$6.9M	↑ 156.33%
Net Income	$-19.1M	↑ 5.83%
Net Profit Margin	-277.65%	↑ 394.84%

	Q4 FY23	Q/Q Change
Revenue	$7.4M	↑ 7.86%
Net Income	$-24.8M	↑ 30.17%
Net Profit Margin	-335.06%	↓ 57.41%

	Q1 FY24	Q/Q Change
Revenue	$36.6M	↑ 394.11%
Net Income	$14.4M	↓ 157.95%
Net Profit Margin	39.3%	↑ 374.36%

	Q2 FY24	Q/Q Change
Revenue	$1.3M	↓ 96.48%
Net Income	$-19.1M	↓ 232.76%
Net Profit Margin	-1.5K%	↓ 1519.53%

	Q3 FY24	Q/Q Change
Revenue	$4.7M	↑ 264.57%
Net Income	$-13.8M	↓ 27.52%
Net Profit Margin	-294.3%	↑ 1185.93%

	FY18	Y/Y Change
Profit	$7.6M	↓ 178.07%

	FY19	Y/Y Change
Profit	$11.9M	↑ 56.53%

	FY20	Y/Y Change
Profit	$19.6M	↑ 63.99%

	FY21	Y/Y Change
Profit	$18.4M	↓ 5.8%

	FY22	Y/Y Change
Profit	$14.2M	↓ 22.76%

	FY23	Y/Y Change
Profit	$16.6M	↑ 16.34%

	Q2 FY23	Q/Q Change
Profit	$1.8M	↓ 19.6%

	Q3 FY23	Q/Q Change
Profit	$6.4M	↑ 251.9%

	Q4 FY23	Q/Q Change
Profit	$6.1M	↓ 3.93%

	Q1 FY24	Q/Q Change
Profit	$36.0M	↑ 486.7%

	Q2 FY24	Q/Q Change
Profit	$1.1M	↓ 96.85%

	Q3 FY24	Q/Q Change
Profit	$4.7M	↑ 314.73%

	FY18	Y/Y Change
Operating Cash Flow	$-15.0M	↑ 25.9%
Investing Cash Flow	$-2.2M	↑ 65.77%
Financing Cash Flow	$6.9M	↓ 88.33%

	FY19	Y/Y Change
Operating Cash Flow	$-41.7M	↑ 178.24%
Investing Cash Flow	$-2.0M	↓ 7.02%
Financing Cash Flow	$109.8M	↑ 1496.84%

	FY20	Y/Y Change
Operating Cash Flow	$-39.3M	↓ 5.73%
Investing Cash Flow	$-2.4M	↑ 18.61%
Financing Cash Flow	$73.4M	↓ 33.1%

	FY21	Y/Y Change
Operating Cash Flow	$-66.0M	↑ 67.81%
Investing Cash Flow	$-12.6M	↑ 430.62%
Financing Cash Flow	$-235.0K	↓ 100.32%

	FY22	Y/Y Change
Operating Cash Flow	$-20.0M	↓ 69.71%
Investing Cash Flow	$-5.0M	↓ 60.12%
Financing Cash Flow	$72.3M	↓ 30853.62%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-19.3M	↑ 578.83%
Investing Cash Flow	$-445.0K	↑ 62.41%
Financing Cash Flow	$45.8M	↓ 6333.33%

Hookipa Pharma Technicals Summary

Sell

Neutral

Buy

Hookipa Pharma is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Hookipa Pharma (HOOK) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Hookipa Pharma Inc.	3.8%	-61.1%	-71.49%	-85.53%	-98.55%
Biontech Se	-0.32%	51.19%	24.81%	-30.66%	288.02%
Regeneron Pharmaceuticals, Inc.	-6.9%	-37.55%	-28.89%	7.15%	74.63%
Vertex Pharmaceuticals Incorporated	16.87%	0.96%	13.03%	93.36%	95.94%
Alnylam Pharmaceuticals, Inc.	17.76%	5.53%	59.46%	84.7%	118.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Hookipa Pharma Inc.	NA	NA	NA	-2.1	-0.49	-0.2	NA	7.45
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.64	16.64	1.08	44.92	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Hookipa Pharma Inc.	Buy	$23.6M	-98.55%	NA	-93.16%
Biontech Se	Buy	$29.7B	288.02%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$74.0B	74.63%	16.64	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$118.9B	95.94%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.0B	118.8%	NA	-15.86%

About Hookipa Pharma

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Organization	Hookipa Pharma
Employees	151
CEO	Dr. Malte Peters M.D.
Industry	Pharmaceuticals: Major

Management People of Hookipa Pharma

Name	Title
Dr. Malte Peters M.D.	CEO & Director
Ms. Mary Theresa Coelho M.B.A.	Executive VP, CFO & Director
Prof. Rolf M. Zinkernagel M.D., Ph.D.	Co-Founder
Mr. Andreas Bergthaler	Co-Founder
Mr. Lukas Flatz	Co-Founder
Dr. Roman Necina Ph.D.	Chief Operations Officer
Dr. Klaus Orlinger Ph.D.	Chief Scientific Officer
Mr. Matthew L. S. Beck	Executive Director of Investor Relations
Mr. Michael Szumera	Executive Director of Communications
Dr. Mark Winderlich Ph.D.	Chief Research & Development Officer

Important FAQs about investing in HOOK Stock from India :

What is Hookipa Pharma share price today?

Hookipa Pharma share price today stands at $1.88, Open: $1.90 ; Previous Close: $1.91 ; High: $1.94 ; Low: $1.84 ; 52 Week High: $10.50 ; 52 Week Low: $1.72.

The stock opens at $1.90, after a previous close of $1.91. The stock reached a daily high of $1.94 and a low of $1.84, with a 52-week high of $10.50 and a 52-week low of $1.72.

Can Indians buy Hookipa Pharma shares?

Yes, Indians can invest in the Hookipa Pharma (HOOK) from India.

With INDmoney, you can buy Hookipa Pharma at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Hookipa Pharma at zero transaction cost.

How can I buy Hookipa Pharma shares from India?

It is very easy to buy Hookipa Pharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Hookipa Pharma (HOOK) be purchased?

Yes, you can buy fractional shares of Hookipa Pharma with INDmoney app.

What are the documents required to start investing in Hookipa Pharma stocks?

To start investing in Hookipa Pharma, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.